Wells Fargo analyst Blaine Heck maintains Corporate Office Props Tr (NYSE:OFC) with a Overweight and lowers the price target from $33 to $30.
Silo Pharma’s New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.
